JP2005507654A5 - - Google Patents

Info

Publication number

JP2005507654A5

JP2005507654A5 JP2003523621A JP2003523621A JP2005507654A5 JP 2005507654 A5 JP2005507654 A5 JP 2005507654A5 JP 2003523621 A JP2003523621 A JP 2003523621A JP 2003523621 A JP2003523621 A JP 2003523621A JP 2005507654 A5 JP2005507654 A5 JP 2005507654A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

test

galr2

galr3

cancer

Prior art date

2002-08-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 claims 52
• 239000008194 pharmaceutical composition Substances 0.000 claims 49
• 239000003112 inhibitor Substances 0.000 claims 27
• 108020004459 Small interfering RNA Proteins 0.000 claims 25
• 210000004027 cell Anatomy 0.000 claims 22
• 101800002068 Galanin Proteins 0.000 claims 21
• 101001072780 Homo sapiens Galanin receptor type 2 Proteins 0.000 claims 21
• 101001072777 Homo sapiens Galanin receptor type 3 Proteins 0.000 claims 21
• 108090000623 proteins and genes Proteins 0.000 claims 20
• 206010028980 Neoplasm Diseases 0.000 claims 18
• 201000011510 cancer Diseases 0.000 claims 18
• 102100036584 Galanin receptor type 2 Human genes 0.000 claims 16
• 102100036588 Galanin receptor type 3 Human genes 0.000 claims 16
• 102400001370 Galanin Human genes 0.000 claims 15
• 241000124008 Mammalia Species 0.000 claims 15
• SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 claims 15
• 108091033319 polynucleotide Proteins 0.000 claims 15
• 239000002157 polynucleotide Substances 0.000 claims 15
• 102000040430 polynucleotide Human genes 0.000 claims 15
• 230000000694 effects Effects 0.000 claims 12
• 230000003042 antagnostic effect Effects 0.000 claims 11
• 108020004414 DNA Proteins 0.000 claims 8
• 230000005907 cancer growth Effects 0.000 claims 8
• 230000002401 inhibitory effect Effects 0.000 claims 8
• 238000012216 screening Methods 0.000 claims 8
• 210000001519 tissue Anatomy 0.000 claims 8
• 230000003902 lesion Effects 0.000 claims 7
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 4
• 108020004491 Antisense DNA Proteins 0.000 claims 4
• 108020005544 Antisense RNA Proteins 0.000 claims 4
• 208000003174 Brain Neoplasms Diseases 0.000 claims 4
• 206010006187 Breast cancer Diseases 0.000 claims 4
• 208000026310 Breast neoplasm Diseases 0.000 claims 4
• 108090000994 Catalytic RNA Proteins 0.000 claims 4
• 102000053642 Catalytic RNA Human genes 0.000 claims 4
• 206010009944 Colon cancer Diseases 0.000 claims 4
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
• 206010033128 Ovarian cancer Diseases 0.000 claims 4
• 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
• 206010060862 Prostate cancer Diseases 0.000 claims 4
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
• 239000003816 antisense DNA Substances 0.000 claims 4
• 208000029742 colonic neoplasm Diseases 0.000 claims 4
• 239000003184 complementary RNA Substances 0.000 claims 4
• 238000009396 hybridization Methods 0.000 claims 4
• 201000005202 lung cancer Diseases 0.000 claims 4
• 208000020816 lung neoplasm Diseases 0.000 claims 4
• 239000002773 nucleotide Substances 0.000 claims 4
• 125000003729 nucleotide group Chemical group 0.000 claims 4
• 238000000159 protein binding assay Methods 0.000 claims 4
• 108091092562 ribozyme Proteins 0.000 claims 4
• 239000002924 silencing RNA Substances 0.000 claims 4
• 150000003384 small molecules Chemical group 0.000 claims 4
• 108091093088 Amplicon Proteins 0.000 claims 3
• 108091034117 Oligonucleotide Proteins 0.000 claims 3
• 241000700605 Viruses Species 0.000 claims 3
• 230000000903 blocking effect Effects 0.000 claims 3
• 210000005260 human cell Anatomy 0.000 claims 3
• 238000001727 in vivo Methods 0.000 claims 3
• 210000004962 mammalian cell Anatomy 0.000 claims 3
• 239000013612 plasmid Substances 0.000 claims 3
• 238000003752 polymerase chain reaction Methods 0.000 claims 3
• 229920001184 polypeptide Polymers 0.000 claims 3
• 230000001124 posttranscriptional effect Effects 0.000 claims 3
• 102000004196 processed proteins & peptides Human genes 0.000 claims 3
• 108090000765 processed proteins & peptides Proteins 0.000 claims 3
• 238000010839 reverse transcription Methods 0.000 claims 3
• 230000001629 suppression Effects 0.000 claims 3
• 241000701161 unidentified adenovirus Species 0.000 claims 3
• 241001515965 unidentified phage Species 0.000 claims 3
• 241001430294 unidentified retrovirus Species 0.000 claims 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 239000005557 antagonist Substances 0.000 claims 1
• 239000012472 biological sample Substances 0.000 claims 1
• 239000012268 protein inhibitor Substances 0.000 claims 1
• 229940121649 protein inhibitor Drugs 0.000 claims 1
• 102000004169 proteins and genes Human genes 0.000 claims 1